These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 37001946)

  • 41. Nucleos(t)ide analogues causes HBV S gene mutations and carcinogenesis.
    Wang ML; Tang H
    Hepatobiliary Pancreat Dis Int; 2016 Dec; 15(6):579-586. PubMed ID: 27919846
    [TBL] [Abstract][Full Text] [Related]  

  • 42. NIH consensus development statement on management of hepatitis B.
    Belongia EA; Costa J; Gareen IF; Grem JL; Inadomi JM; Kern ER; McHugh JA; Petersen GM; Rein MF; Sorrell MF; Strader DB; Trotter HT
    NIH Consens State Sci Statements; 2008 Oct 22-24; 25(2):1-29. PubMed ID: 18949020
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B.
    Bayliss J; Yuen L; Rosenberg G; Wong D; Littlejohn M; Jackson K; Gaggar A; Kitrinos KM; Subramanian GM; Marcellin P; Buti M; Janssen HLA; Gane E; Sozzi V; Colledge D; Hammond R; Edwards R; Locarnini S; Thompson A; Revill PA
    Gut; 2017 Nov; 66(11):2013-2023. PubMed ID: 27534671
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon?
    Kao JH
    Liver Int; 2014 Feb; 34 Suppl 1():112-9. PubMed ID: 24373087
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment.
    Gil-García AI; Madejón A; Francisco-Recuero I; López-López A; Villafranca E; Romero M; García A; Olveira A; Mena R; Larrubia JR; García-Samaniego J
    World J Gastroenterol; 2019 Oct; 25(38):5883-5896. PubMed ID: 31636479
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Short- and long-term outcome of interferon therapy for chronic hepatitis B infection.
    Seo Y; Yano Y
    World J Gastroenterol; 2014 Oct; 20(37):13284-92. PubMed ID: 25309065
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Standardized Hepatitis B Virus RNA Quantification in Untreated and Treated Chronic Patients: a Promising Marker of Infection Follow-Up.
    Cortese MF; Riveiro-Barciela M; Tabernero D; Rodriguez-Algarra F; Palom A; Sopena S; Rando-Segura A; Roade L; Kuchta A; Ferrer-Costa R; Quer J; Pacin B; Vila M; Casillas R; Garcia-Garcia S; Esteban R; Pumarola T; Buti M; Rodriguez-Frias F
    Microbiol Spectr; 2022 Apr; 10(2):e0214921. PubMed ID: 35377229
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of on-treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection.
    Choi HSJ; Sonneveld MJ; Farag MS; Brouwer WP; Brakenhoff SM; Hirode G; Gehring AJ; de Man RA; Hansen BE; Janssen HLA
    J Viral Hepat; 2021 Dec; 28(12):1729-1737. PubMed ID: 34514678
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
    Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
    Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hepatitis B.
    Jeng WJ; Papatheodoridis GV; Lok ASF
    Lancet; 2023 Mar; 401(10381):1039-1052. PubMed ID: 36774930
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues.
    Buster EH; Schalm SW; Janssen HL
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1093-108. PubMed ID: 19187869
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.
    Lai CL; Wong D; Ip P; Kopaniszen M; Seto WK; Fung J; Huang FY; Lee B; Cullaro G; Chong CK; Wu R; Cheng C; Yuen J; Ngai V; Yuen MF
    J Hepatol; 2017 Feb; 66(2):275-281. PubMed ID: 27639844
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.
    Seto WK; Liu K; Wong DK; Fung J; Huang FY; Hung IF; Lai CL; Yuen MF
    J Hepatol; 2013 Oct; 59(4):709-16. PubMed ID: 23792029
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.
    Wong DK; Seto WK; Fung J; Ip P; Huang FY; Lai CL; Yuen MF
    Clin Gastroenterol Hepatol; 2013 Aug; 11(8):1004-10.e1. PubMed ID: 23376799
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunopathogenesis of Hepatitis B Virus.
    Tseng TC; Huang LR
    J Infect Dis; 2017 Nov; 216(suppl_8):S765-S770. PubMed ID: 29156047
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B.
    Song JC; Min BY; Kim JW; Kim JY; Kim YM; Shin CM; Lee SH; Hwang JH; Jeong SH; Kim N; Lee DH
    Korean J Hepatol; 2011 Dec; 17(4):268-73. PubMed ID: 22310791
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.
    Uchida T; Imamura M; Hayes CN; Hiraga N; Kan H; Tsuge M; Abe-Chayama H; Zhang Y; Makokha GN; Aikata H; Miki D; Ochi H; Ishida Y; Tateno C; Chayama K
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696237
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Drugs in the Pipeline for HBV.
    Lopatin U
    Clin Liver Dis; 2019 Aug; 23(3):535-555. PubMed ID: 31266626
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B.
    Reijnders JG; Perquin MJ; Zhang N; Hansen BE; Janssen HL
    Gastroenterology; 2010 Aug; 139(2):491-8. PubMed ID: 20381492
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sustained viral response and relapse after discontinuation of oral antiviral drugs in HBeAg-positive patients with chronic hepatitis B infection.
    Sun F; Li Z; Hu L; Deng W; Jiang T; Wang S; Bi X; Lu H; Yang L; Lin Y; Zeng Z; Shen G; Liu R; Chang M; Wu S; Gao Y; Hao H; Xu M; Chen X; Zhang L; Lu Y; Dong J; Xie Y; Li M
    Front Immunol; 2022; 13():1082091. PubMed ID: 36505492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.